CDIO vs DBVT vs ALKS vs HLIO

For growth investors, Cardio Diagnostics Holdings, Inc.

(CDIO) is the stronger pick with 104. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Cardio Diagnostics Holdings, Inc. (CDIO) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.

8x versus Helios Technologies, Inc. at 46. 9x.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 4% for Cardio Diagnostics Holdings, Inc. (CDIO). Over 10 years, the gap is even starker: HLIO returned +109. 8% versus CDIO's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Cardio Diagnostics Holdings, Inc. 's 3. 00β — meaning CDIO is approximately 183% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cardio Diagnostics Holdings, Inc.

(CDIO) is pulling ahead at 104. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Cardio Diagnostics Holdings, Inc. grew EPS 53. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, CDIO leads at 238. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -240. 3% for Cardio Diagnostics Holdings, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -239. 8% for CDIO. At the gross margin level — before operating expenses — CDIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, HLIO (0.

5% yield) pays a dividend. CDIO, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Helios Technologies, Inc.

(HLIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield, +109. 8% 10Y return). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 3. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HLIO: +109. 8%, CDIO: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDIO (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and HLIO (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CDIO is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; HLIO is a small-cap quality compounder stock. HLIO pays a dividend while CDIO, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.